UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

☒	Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended June 30, 2022
	For the quarterly period ended December 31, 2022
☐	Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
	For the transition period from to __________
	Commission File Number: 333-146834

Regenicin, Inc.
(Exact name of registrant as specified in its charter)

Nevada	27-3083341
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

OTCBB	RGIN	COMMON
Principal US Market	Symbol	Class of Trading Security

10 High Court, Little Falls, NJ 07424

(973) 557-8914

(Address of principal executive offices)

(Registrant’s telephone number)

_______________________________________________________________
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐Yes ☒No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☐Yes ☒No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.

Large accelerated filer	☐	Non-accelerated Filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐Yes ☒No

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 153,483,050 as of ~~July~~January 2620, ~~2022~~2023.

NOTICE: THIS 10Q FILING DOES NOT CONTAIN FINANCIAL OR OTHER INFORMATION WHICH HAS BEEN AUDITED OR REVIEWED BY OUR INDEPENDENT PUBLIC ACCOUNTING FIRM FOR REASONS SPECIFIED HEREIN. WE INTEND TO SUPPLEMENT THIS FILING, AT A CURRENTLY UNKNOWN LATER DATE, WITH SUCH REVIEWED AND AUDITED FINANCIAL INFORMATION, IF AND WHEN SUCH REVIEW AND AUDIT CAN BE OBTAINED.

Table of Contents

	TABLE OF CONTENTS	Page

PART I – FINANCIAL INFORMATION

Item 1:	Financial Statements	3
Item 2:	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4
Item 3:	Quantitative and Qualitative Disclosures About Market Risk	7
Item 4:	Controls and Procedures	7
PART II – OTHER INFORMATION
Item 1:	Legal Proceedings	8
Item 1A:	Risk Factors	8
Item 2:	Unregistered Sales of Equity Securities and Use of Proceeds	8
Item 3:	Defaults Upon Senior Securities	8
Item 4:	Mine Safety Disclosures	8
Item 5:	Other Information	8
Item 6:	Exhibits	8

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Our consolidated financial statements included in this Form 10-Q are as follows:

The consolidated financial statements as of and for the three months ended ~~June~~December 3031, 2022 and 2021 have not been reviewed by our independent registered public accounting firm. The consolidated balance sheet as September 30, ~~2021~~2022 has not been audited by our independent registered public accounting firm.

F-1	Consolidated Balance Sheets as of ~~June~~December 3031, 2022 (unreviewed) and September 30, ~~2021~~2022 (unaudited);
F-2	Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~June~~December 3031, 2022 and 2021 (unreviewed);
F-3	Consolidated Statements of Stockholders’ Deficiency for the ~~nine~~three months ended ~~June~~December 3031, 2022 and 2021 (unreviewed);
F-4	Consolidated Statements of Cash Flows for the three ~~and nine~~ months ended ~~June~~December 3031, 2022 and 2021 (unreviewed); and
F-5	Notes to Consolidated Financial Statements.

These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the SEC instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended ~~June 30,~~December 31, 2022 are not necessarily indicative of the results that can be expected for the full year.

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

(UNREVIEWED AND UNAUDITED)

	June 30, 2022			September 30, 2021
	December 31, 2022			September 30, 2022
		(Unreviewed)			(Unaudited)
ASSETS
CURRENT ASSETS
Cash	$	111,~~643~~793,901		$	114,~~859~~568
Common stock of Amarantus		~~600~~425			~~2,750~~925
Total current and total assets	$	2,243		$	4,609
Deferred income taxes		—			—
Total current and total assets	$	11,794,326		$	15,493
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Accounts payable	$	855,~~000~~279		$	93103,~~674~~119
Accrued expenses - other (related party of $60,575 and $46,713)		262,319			234,894
Accrued expenses - other (related party of $70,455 and $65,471)		267,657			254,595
Accrued salaries - officers		4,~~466~~612,~~751~~001			4,~~031~~612,001
Deferred income		12,141,125			—
Promissory note payable		175,000			175,000
Convertible promissory note - officer		335,683			335,683
Loan payable		10,000			10,000
Loans payable - officer		~~109~~122,235			82122,235
Total current liabilities	$	517,~~443~~668,~~988~~980		$	45,~~962~~612,~~487~~633
STOCKHOLDERS' DEFICIENCY
Series A 8% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized; 885,000 issued and outstanding		885			885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 issued and 153,483,050 outstanding		157,914			157,914
Additional paid-in capital		10,208,339			10,208,339
Accumulated deficit		(1516,~~804~~237,~~455~~364	)		(15,~~320~~959,~~588~~850	)
Less: treasury stock; 4,428,360 shares at par		(4,428	)		(4,428	)
Total stockholders' deficiency		(5,~~441~~874,~~745~~654	)		(45,~~957~~597,~~878~~140	)
Total liabilities and stockholders' deficiency	$	211,~~243~~794,326		$	415,~~609~~493

See Notes to Consolidated Financial Statements.

F-14

Table of Contents

REGElNICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNREVIEWED)

	Nine Months Ended June 30, 2022			Nine Months Ended June 30, 2021			Three Months Ended June 30, 2022			Three Months Ended June 30, 2021
	Three Months Ended December 31, 2022			Three Months Ended December 31, 2021
Revenues	$	—		$	—		$	—		$	—
Operating expenses
General and administrative		~~454~~267,~~766~~619			~~532~~146,~~113~~532			~~152,721~~			~~155,559~~
Total operating expenses		~~454~~267,~~766~~619			~~532~~146,~~113~~532			~~152,721~~			~~155,559~~
Operating loss before other operating income		(~~454~~267,~~766~~619	)		(~~532~~146,~~113~~532	)		~~(152,721~~	)		~~(155,559~~	)
Other operating income - reversal of accounts payable		—			—			—			—
Other income (expenses)
Loss from operations		(454,766	)		(532,113	)		(152,721	)		(155,559	)
Interest expense (related party of $4,984 and $4,532)		(9,395	)		(8,943	)
Other income (expenses)
Change in unrealized gain (loss) on securities		(500	)		1,350
Interest expense (related party of $13,862, $12,425, $4,730 and $4,448)		(26,951	)		(25,514	)		(8,997	)		(8,811	)
Total other expenses		(9,895	)		(7,593	)
Change in unrealized gain (loss) on securities		(2,150	)		(900)			(1,375	)		(975	)
Net loss		(277,514	)		(154,125	)
Total other expenses		(29,101	)		(26,414	)		(10,372	)		(9,786	)
Preferred stock dividends		(17,845	)		(17,845	)
Net loss		(483,867	)		(558,527	)		(163,093	)		(165,345	)
Net loss attributable to common stockholders	$	(295,359	)	$	(171,970	)
Preferred stock dividends		(52,954	)		(52,954	)		(17,561	)		(17,651	)
Loss per share basic	$	(0.00	)	$	(0.00	)
Net loss attributable to common stockholders	$	(536,821	)	$	(611,481	)	$	(180,744	)	$	(182,996	)
Loss per share diluted	$	(0.00	)	$	(0.00	)
Loss per share basic	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Weighted average number of shares outstanding basic		153,483,050			153,483,050
Loss per share diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Weighted average number of shares outstanding diluted		153,483,050			153,483,050
Weighted average number of shares outstanding basic		153,483,050			153,483,050			153,483,050			153,483,050
Weighted average number of shares outstanding diluted		153,483,050			153,483,050			153,483,050			153,483,050

See Notes to Consolidated Financial Statements.

F-25

Table of Contents

REGENICIN, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY
(UNREVIEWED)

									Additional
	Convertible Preferred Stock				Common Stock				Paid-in		Accumulated			Treasury
	Shares		Amount		Shares		Amount		Capital		Deficit			Stock (1)			Total
Balances at October 1, 2021		885,000	$	885		157,911,410	$	157,914	$	10,208,339	$	(15,320,588	)	$	(4,428	)		(4,957,878	)
Balances at October 1, 2022		885,000	$	885		157,911,410	$	157,914	$	10,208,339	$	(15,959,850	)	$	(4,428	)		(5,597,140	)
Net Loss		—		—		—		—		—		(277,514	)		—			(277,514	)
Balances at December 31, 2022		885,000		885		157,911,410		157,914		10,208,339		(16,237,364	)		(4,428	)		(5,874,654	)
Balances at October 1, 2021		885,000		885		157,911,410		157,914		10,208,339		(14,649,986	)		(4,428	)		(4,287,276	)
Net Loss		—		—		—		—		—		(154,125	)		—			(154,125	)
Balances at December 31, 2021		885,000	$	885		157,911,410	$	157,914	$	10,208,339	$	(1514,~~474~~804,~~713~~111	)	$	(4,428	)	$	(4,~~287~~441,~~276~~401	)
Net Loss		—		—		—		—		—		(166,649	)		—			(166,649	)
Balances at March 31, 2022		885,000		885		157,911,410		157,914		10,208,339		(15,641,362	)		(4,428	)		(5,278,652	)
Net Loss		—		—		—		—		—		(163,093	)		—			(163,093	)
Balances at June 30, 2022		885,000	$	885		157,911,410	$	157,914	$	10,208,339	$	(15,804,488	)	$	(4,428	)	$	(5,604,838	)
Balances at October 1, 2020		885,000	$	885		157,911,410	$	157,914	$	10,208,339	$	(14,649,986	)	$	(4,428	)	$	(4,287,276	)
Net loss		—		—		—		—		—		(159,878	)		—			(159,878	)
Balances at December 31, 2020		885,000		885		157,911,410		157,914		10,208,339		(14,809,864	)		(4,428	)		(4,447,154	)
Net Loss		—		—		—		—		—		(233,304	)		—			(233,304	)
Balances at March 31, 2021		885,000		885		157,911,410		157,914		10,208,339		(15,208,339	)		(4,428	)		(4,680,458	)
Net Loss		—		—		—		—		—		(165,345	)		—			(165,345	)
Balances at June 30, 2021		885,000	$	885		157,911,410	$	157,914	$	10,208,339	$	15,208,513	)	$	(4,428	)	$	(4,845,803	)

(1)

The number of shares in treasury stock for all periods presented was 4,428,360.

See Notes to Consolidated Financial Statements.

F-36

Table of Contents

REGENICIN, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNREVIEWED)

	Nine Months Ended June 30,			Nine Months Ended June 30,
	Three Months Ended December 31,			Three Months Ended December 31,
	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(~~483~~277,~~867~~514	)	$	(~~558~~154,~~527~~125	)
Adjustments to reconcile net loss to net cash used in operating activities:
Unrealized loss on investment		~~2,150~~500			~~900~~(1,350	)
Accrued interest on loans and notes payable		269,~~952~~395			258,~~514~~943
Changes in operating assets and liabilities
Accrued interest income on due from related party
Accounts payable		(897,~~676~~840	)		5(8,~~016~~676	)
Accrued expenses - other		~~475~~3,667			~~69,187~~(674	)
Accrued salaries - officers		~~435,750~~—			~~435~~145,~~749~~250
Net cash used in operating activities		(27361,~~216~~792	)		(2210,~~161~~632	)
CASH FLOWS FROM FINANCING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds of loans from officers		~~27,000~~—			2310,~~600~~500
Net cash provided by financing activities		27,000			23,600
Proceeds from the sale of partnership interests		12,141,125			—
NET DECREASE IN CASH		(216	)		1,439
Net cash provided by financing activities		12,141,125			10,500
CASH - BEGINNING OF PERIOD		1,859			1,366
NET INCREASE IN CASH		11,779,333			(132	)
CASH - END OF PERIOD	$	1,643		$	2,805
CASH - BEGINNING OF PERIOD		14,568			1,859
CASH - END OF PERIOD	$	11,793,901		$	1,727
Supplemental disclosures of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—

See Notes to Consolidated Financial Statements.

F-47

Table of Contents

~~NOTES TO~~REGENICIN, ~~THE~~INC. ~~CONSOLIDATED~~AND ~~FINANCIAL STATEMENTS (UNAUDITED )~~SUBSIDIARY

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(UNREVIEWED)

NOTE 1 - THE COMPANY

Regenicin, Inc. ("Regenicin"), formerly known as Windstar, Inc., was incorporated in the state of Nevada on September 6, 2007. On July 19, 2010, the Company ~~amended~~ amended its Articles of Incorporation to change the name of the Company to Regenicin, Inc. InOn ~~September~~August ~~2013~~31, ~~Regenicin~~2022, ~~formed~~we afiled ~~new~~articles ~~wholly-owned~~of ~~subsidiary~~continuance ~~for~~with the ~~sole~~states ~~purpose~~ of ~~conducting~~Nevada ~~research~~and inWyoming ~~the~~effectively ~~State~~moving ofour ~~Georgia~~organizational ~~(together,~~jurisdiction ~~the~~from ~~"Company").~~Nevada ~~The~~to ~~subsidiary has~~Wyoming noeffective ~~activity~~on ~~since~~that ~~its formation due to the lack of funding~~date. The Company's business plan is to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

In October 2022, the Company set up a new Nevada Series LLC called NovaDerm Product Package, LLC (“NPP LLC”). During November and December 2022, consistent with Nevada law governing this Master Series LLC, the Company established twenty-five (25) individual series LLCs, identifying each with a series letter of A through T or AA through EE. Thus, each of these sub-entities were named NovaDerm Product Package Series A, LLC through Series T, LLC, and then Series AA to Series EE, LLC (or NPP-A through NPP-T and NPP-AA through NPP-EE for short).

Into each of these twenty-five individual Series LLCs, the Company contributed the right and exclusive ownership to a certain amount of the bovine hides and corium that the Company currently owned and used as key materials in the preparation of its NovaDerm® product, as well as the right to designate: (a) the specific patient cultured skin to be prepared from these materials; (b) the amount of this cultured skin to be prepared up to a designated amount and (c) the medical facility to receive the fully prepared and processed NovaDerm® cultured skin from these materials (these materials and combined designation rights are collectively referred to herein as the “NovaDerm® Product Rights”). For NPP-A through NPP-T and NPP-AA through NPP-CC the Company designated 33,333 cm² of these NovaDerm® Product Rights. For NPP-DD they designated 30,625 cm² of NovaDerm® Product Rights and for NPP-EE they designated 28,783 cm² of NovaDerm® Product Rights. Each contribution of each of the NovaDerm® Product Rights was provided in exchange for 100 membership interests in the Series LLC which represented 100% of all membership interests issued.

The Company subsequently transferred 99% of their membership interests (or 99 membership interests) in each of these Series LLC to various Limited Liability Companies, held by individuals unknown to us, in exchange for a pre-agreed payment. Prior to December 31, 2022, the members of these LLCs voted to donate 100% of the membership interests to charity.

While the Company retains possession of the materials transferred in each Series LLC contribution, the Company has a continuing obligation to segregate and manage those materials as well as to prepare the NovaDerm® cultured skin product as designated by each Series LLC holder or their designate. The identified materials are currently set apart from other such materials and are being held by the Company pending the identification of the patient and medical facility as instructed by each NovaDerm® Product Rights holder. Notwithstanding this retention of possession by the Company, the ownership and legal title to the materials are retained and fully vested in the individual Series LLC or its designate.

The above-described transfers of membership interests in the Series LLCs generated a substantial amount of cash which we are obligated to use for the completion of our NovaDerm IND and the administration of our product clinical trials. No assurance, however, can be given as to the success or failure of such IND or clinical trials, or as to any future FDA decisions made following these trials. Due to the continuing obligation the Company recorded the amount received as deferred income.

F-8

Table of Contents

NOTE 2 - BASIS OF PRESENTATION

Interim Financial Statements:

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of those of a recurring nature) considered necessary for a fair presentation have been included. Operating results for the ~~nine~~three months ended ~~June~~December 3031, 2022, are not necessarily indicative of the results that may be expected for the year ending September 30, ~~2022~~2023. These unaudited consolidated financial statements should be read in conjunction with the unaudited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K/A for the year ended September 30, ~~2021~~2022, as filed with the Securities and Exchange Commission. The consolidated balance sheet as of September 30, ~~2021~~2022, contained herein has been derived from the unaudited consolidated financial statements as of September 30, ~~2021~~2022, but does not include all disclosures required by U.S. GAAP.

Going Concern:

The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred recurring losses and as of ~~June~~December 3031, 2022, has an accumulated deficit of approximately $1516.82 million from inception, expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt, ~~and~~ private ~~sale~~ sale of equity securities, and recently the certain partnership interest. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Currently management plans to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Financial Instruments and Fair Value Measurement:

As of October 1, 2018, the Company adopted ASU No. 2016-01, “Financial Instruments-Overall: Recognition and Measurement of Financial Assets and Financial Liabilities”. The new standard principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of the new standards, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There no longer is an available-for-sale classification and therefore, no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. As a result of the adoption, the Company recorded a cumulative effect adjustment of a $950 decrease to accumulated other comprehensive income, and a corresponding decrease to accumulated deficit, as of October 1, 2018.

Common stock of Amarantus BioScience Holdings, Inc. (“Amarantus”) is carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, and unrealized gains and losses are included in other income (expense) on the statement of operations.

The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at ~~June~~December 3031, 2022 is $~~600~~425. The change in unrealized gain (loss) for the ~~nine and~~ three months ended ~~June~~December 3031, 2022 and 2021 was $~~150,~~(500) and $1,~~375,~~350 ~~$900 and $975~~ net of income taxes, respectively, and was reported as other income (expense).

Recently Issued Accounting Pronouncements:

Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the consolidated financial statements of the Company.

F-59

Table of Contents

NOTE 3 - LOSS PER SHARE

Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive.

The following weighted average securities have been excluded from the calculation ~~even~~of ~~though~~net ~~the~~loss ~~exercise~~per ~~price~~share ~~was~~for ~~less~~the ~~than~~three ~~the~~months ~~average~~ended ~~market~~December ~~price~~31, of2022 ~~the~~and ~~common~~2021 ~~shares~~as ~~because~~ the ~~effect~~exercise ofprice ~~including these potential shares~~ was ~~anti-dilutive~~greater ~~due~~than to the ~~net~~average ~~losses~~market ~~incurred during~~price of the ~~nine~~common ~~months ended June 30, 2022 and 2021~~shares:

	2022		2021
Options		11,771,344		11,771,~~344~~334
Convertible Preferred Stock		8,850,000		8,850,000
Convertible Promissory Note		27,078,816		11,615,329
		46,700,160		32,236,673

The following weighted average securities have been excluded from the calculation because the effect of including these potential shares was anti-dilutive due to the net losses incurred during the three months ended December 31, 2022 and 2021:

	2022		2021
Convertible Preferred Stock		8,850,000		8,850,000
Convertible Promissory Note		56,123,437		17,493,789
		64,973,437		26,473,789

NOTE 4 – LOANS PAYABLE

Convertible Promissory Note – Officer

Through March 31, 2020, John Weber, the Company's Chief Financial Officer, advanced the Company a total of $335,683. On March 31, 2020, these advances were converted into a convertible promissory note. Interest on the note is computed at 5% per annum and accrues from the time of the advances until the maturity date. The original maturity date was September 30, 2020, at which time all the accrued interest and principal became due. The note has been extended several times and most recently to ~~September~~December 3031, 2022. For the ~~nine and~~ three months ended December ~~June 30~~31, 2022 and 2021 interest totaling $~~13,862,~~984 ~~$4,730, $12,425~~ and $4532,~~448,~~ respectively, aswas incurred. Accrued interest on the note was $6070,~~575~~455 and $4665,~~713~~471 at ~~June~~December 3031, 2022 and ~~September~~December 3031, 2021, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets. The note is convertible at the option of Mr. Weber into shares of the Company's common stock at the prevailing market rate on the date of conversion.

Loan Payable:

In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both ~~June~~December 3031, 2022 and ~~September~~ 30December 31, 2021, the loan payable totaled $10,000.

Loans Payable - Officer:

Through September 30, 2020, J. Roy Nelson, the Company’s Chief Science Officer, made net advances to the Company totaling $26,935. The loans do not bear interest and are due on demand.

In September 2018, Randall McCoy, the Company’s Chief Executive Officer, advanced to the Company $4,500. The loan does not bear interest and is due on demand.

From July 2020 through ~~June 30,~~ September 2022, John Weber, the Company’s Chief Financial Officer, advanced to the Company $7790,800. The loan bears interest at 5% per annum and is due on demand.

F-610

Table of Contents

NOTE 5 - BRIDGE FINANCING

On December 21, 2011, the Company issued a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date of June 21, 2012. Additional interest of 10% was charged on any late payments. The note was not paid at the maturity date and the Company is incurring additional interest as described above. At both ~~June~~December 3031, 2022 and September 30, ~~2021~~2022, the note balance was $175,000. ~~For~~Interest ~~the~~expense ~~nine~~was ~~and~~$4,411 ~~three~~for both ~~months~~quarters ended ~~June~~December 3031, 2022 and 2021~~, interest totaling $13,089, $4,267, $13,139, and $4,363 respectively, was incurred~~. Accrued interest on the note was $~~175~~184,~~527 and~~349 and $~~162~~179,~~438 as~~938 as of ~~June~~December 3031, 2022 and September 30, ~~2021~~2022, respectively, and is included in Accrued expenses - other in the accompanying ~~consolidated~~ consolidated balance sheets.

NOTE 6 - INCOME TAXES

The Company recorded no income tax expense for the ~~nine~~three months ended ~~June~~December 3031, 2022 and 2021 because the estimated annual effective tax rate was zero. As of ~~June~~December 3031, 2022, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

NOTE 7 – STOCKHOLDERS' DEFICIENCY

Preferred Stock:

Series A

At both ~~June~~December 3031, 2022 and September 30, ~~2021~~2022, 885,000 shares of Series A Preferred Stock (“Series A Preferred”) were outstanding.

Series A Preferred pays a dividend of 8% per annum on the stated value and has a liquidation preference equal to the stated value of the shares ($885,000 liquidation preference as of ~~June~~December 3031, 2022 and September 30, ~~2021~~2022 plus dividends in arrears as per below). Each share of Series A Preferred Stock has an initial stated value of $1.00 and is convertible into shares of the Company’s common stock at the rate of 10 for 1.

The Series A Preferred Stock was marketed through a private placement memorandum that included a reference to a ratchet provision which would have allowed the holders of the stock to claim a better conversion rate based on other stock transactions conducted by the Company during the three-year period following the original issuance of the shares. The Certificate of Designation does not contain a ratchet provision. Certain of the stock related transactions consummated by the Company during this time period may have triggered this ratchet provision, and thus created a claim by holders of the Series A Preferred Stock who purchased based on this representation for a greater conversion rate than initially provided. There have been no new developments related to the remaining Series A holders regarding this claim and the conversion rate of their Series A Preferred Stock. Changes to the preferred stock conversion ratio may result in modification or extinguishment accounting. That may result in a deemed preferred stock dividend which would reduce net income available to common stockholders in the calculation of earnings per share. Certain of the smaller Series A holders have already converted or provided notice of conversion of their shares. In respect of this claim, the Company and its outside counsel determined that it is not possible to offer an opinion regarding the outcome. An adverse outcome could materially increase the accumulated deficit.

The dividends are cumulative commencing on the issue date when and if declared by the Board of Directors. As of ~~June~~December 3031, 2022, and September 30, ~~2021~~2022, dividends in arrears were $~~800~~835,~~184~~875 ($.9094 per share) and $~~747~~818,~~232~~030 ($.8482 per share), respectively.

Series B

Four million (4,000,000) shares of Series B Convertible Preferred Stock (“Series B Preferred”) have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Preferred have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Preferred, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At June 30, 2022, no shares of Series B Preferred are outstanding.

F-711

Table of Contents

NOTE 8 - STOCK-BASED COMPENSATION

The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505, “Equity.” Costs are measured at the estimated fair value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC 505.

NOTE 9 - RELATED PARTY TRANSACTIONS

The Company’s principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.

The Company also maintains an office at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory. An officer of the Company is an owner of CPR.

NoThe Company paid rent no rent for the three months ended December 31, 2022. No rent iswas charged for ~~either premise~~previously.

On May 16, 2016, the Company entered into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue. The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other customers. The Company has not yet made purchases from CPR.

See Note 4 for loans payable to related parties.

NOTE 10 - SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date of this filing.

F-812

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

Overview of key events of the first quarter ended December 31, 2022

~~The~~During ~~company’s major~~the ~~objective~~first ~~for~~quarter ended December 31, 2022, we ~~remains~~began a program of pre-packaging and transferring materials and rights to ~~secure~~set ~~the~~amounts ~~required~~of ~~funding~~our NovaDerm® product to ~~finalize~~certain ~~some~~individuals through ~~additional~~new ~~requirements~~series ofLLCs. ~~the~~These ~~IND~~individuals ~~application~~were interested in acquiring our product materials and ~~begin~~ rights for the ~~clinical~~purpose ~~trials~~of transferring them to charitable foundations interested in medical solutions for burn victims.

~~We estimated~~As ~~that~~part ~~the completion~~ of ~~the~~this ~~IND~~process, ~~and~~in ~~the~~October ~~clinical~~2022, ~~trials~~we ~~would~~set ~~take~~up a ~~approximately~~new ~~12-18~~Nevada ~~months~~Series ~~and~~LLC ~~cost~~called inNovaDerm ~~the~~Product ~~range~~Package, ofLLC $6(“NPP LLC”).~~9 million~~ ~~once~~During ~~initial~~November ~~funding~~and isDecember in2022, ~~place.~~consistent Itwith Nevada islaw ~~estimated~~governing ~~that~~this ~~the~~Master ~~cost~~Series toLLC, ~~finalize~~we ~~the~~establish ~~IND~~twenty-five ~~will~~(25) beindividual ~~approximately~~series ~~1.9 million~~LLCs, ~~and~~identifying ~~the cost~~each towith ~~complete~~a ~~Phase~~series ~~1/2~~ letter of ~~the~~A ~~clinical~~through ~~trial~~T ~~will~~or beAA ~~approximately~~through 5EE.0 ~~million.~~Thus, Ineach ~~addition~~of tothese ~~the~~sub-entities ~~completion~~were ofnamed ~~the~~NovaDerm ~~IND~~Product Package Series A, ~~the~~LLC ~~only~~through Series T, ~~other~~LLC, ~~significant~~and ~~gating~~then ~~item~~Series AA to ~~entering~~Series ~~the~~EE, ~~clinical~~LLC ~~trials~~(or isNPP-A ~~funding~~through ~~for~~NPP-T ~~this~~and ~~process~~NPP-AA through NPP-EE for short).

Into each of these twenty-five individual Series LLCs, we contributed the right and exclusive ownership to a fixed amount of the bovine hides and corium we currently own and use as key materials in the preparation of our NovaDerm® product, as well as the right to designate: (a) the specific patient cultured skin to be prepared from these materials; (b) the amount of this cultured skin to be prepared up to a designated amount and (c) the medical facility to receive the fully prepared and processed NovaDerm® cultured skin from these materials (these materials and combined designation rights are collectively referred to herein as the “NovaDerm® Product Rights”). For NPP-A through NPP-T and NPP-AA through NPP-CC we designated 33,333 cm² of these NovaDerm® Product Rights. For NPP-DD we designated 30,625 cm² of NovaDerm® Product Rights and for NPP-EE we designated 54,950 cm² of NovaDerm® Product Rights. Each contribution of each of the NovaDerm® Product Rights was provided in exchange for 100 membership interests in the Series LLC which represented 100% of all membership interests issued.

We subsequently transferred 99% of our membership interests (or 99 membership interests) in each of these Series LLC to various Limited Liability Companies, held by individual’s unknown to us, in exchange for a pre-agreed payment.

While we retain possession of the materials transferred in each Series LLC contribution, we have a continuing obligation to segregated and manage those materials as well as to prepare the NovaDerm® cultured skin product as designated by each Series LLC holder or their designate. The identified materials are currently set apart from other such materials and are being held by us pending the identification of the patient and medical facility as instructed by each NovaDerm® Product Rights holder. Notwithstanding this retention of possession by us, the ownership and legal title to the materials are retained and fully vested in the individual Series LLC or its designate.

Table of Contents

AsOur ~~previously~~major ~~reported,~~objective for 2023 remains to complete the requirements of our ~~goal~~NovaDerm inIND ~~obtaining~~application ~~this~~and ~~funding~~begin ~~has~~our ~~been~~clinical trials. It is estimated that the cost to ~~minimize~~ ~~shareholders'~~finalize ~~dilution~~the asIND ~~much~~will asbe approximately ~~possible~~$1.9 ~~Consequently~~million dollars, and the cost to complete Phase 1/2 of the clinical trial will be approximately 5.0 million dollars. There can be no assurance that we ~~are~~will ~~continuing~~be able to ~~pursue~~complete ~~financing~~these ~~through~~tasks for these estimated amounts or that we will be successful in the proving ~~issuance~~out ofour aNovaDerm® ~~debt~~Product in this process. Indeed, clinic trials are notoriously difficult and expensive and are likely to ~~instrument~~result in additional unplanned costs and ~~international~~a ~~licensing~~denial ~~agreements~~of FDA approval.

WeAs ~~continue~~previously reported, our goal in obtaining funding for this process has been to ~~work~~minimize ~~with~~shareholders' adilution ~~number~~as much as possible. We believe the manner in which we structured our transfer of NovaDerm® Product Rights has successfully achieved this objective. We will continue to work with potential investors, as necessary, ~~and~~in ~~continue~~order to pursue ~~the~~other necessary funding based on our stated ~~objectives~~objective of successfully completing our planned clinical trials and obtaining FDA approval for the commercial sale of our NovaDerm® Product. It has taken longer to raise the funds than originally estimated; however, we remain ~~confident~~hopeful that our goal is now achievable. ~~In the interim, the officers and related parties intend to continue to fund the Company’s essential operating costs.~~

WeIn ~~have continued~~ the ~~planning~~preparation ~~for~~of the ~~clinical~~IND ~~trials~~application, we will continue to develop the ~~extent~~testing wesuggested ~~are~~by ~~able,~~the ~~considering~~FDA ~~funding~~during ~~constraints~~our Pre-IND meeting. AsOur ~~previously~~scaffold ~~reported~~supplier wecontinues ~~have~~to ~~chosen~~perform athe ~~CRO~~FDA tosuggested testing ~~assist~~on incollagen ~~our~~processing ~~IND~~which ~~submission and~~addresses ~~conducting~~Bovine ~~the~~Closed ~~trials.~~Herd Werequirements ~~have~~for ~~identified~~the enhanced safety and ~~received~~traceability ~~quotes~~of ~~from~~the ~~potential~~collagen scaffolds ~~NovaDerm~~used ~~contract~~to ~~manufacturers~~produce NovaDerm®. ~~Clinical~~We ~~site~~will ~~selection and~~be ~~patient~~entering ~~recruitment~~into ~~should~~discussions beand ~~somewhat~~evaluation ~~simpler~~of ~~than~~possible ~~other~~ clinical ~~trials,~~trial sites for NovaDerm® as we ~~are~~proceed ~~limited~~through inthe ~~site~~FDA ~~selection~~approval toprocess. ~~the~~Our ~~127~~discussions ~~burn~~so ~~centers~~far have confirmed that patient recruitment ~~qualified~~and toenrollment ~~treat~~should ~~pediatric~~be faster and ~~adult~~less ~~full~~complicated ~~thickness~~than ~~catastrophic~~other ~~burns.~~clinical Intrials ~~addition,~~because of our Orphan Designation and the fact that the surgical protocol will be similar to the ~~split thickness~~grafting ~~allografting~~ procedures currently in use at ~~those~~most facilities. NovaDerm® should thus require minimal physician training and documentation to complete the clinical trial, when and if conducted.

~~The~~We are in the process of preparing a detailed plan and timeline for the filing of our IND and commencement of clinical trials and will provide this information when complete and approved by our board of directors. Our initial trials are planned to begin with a total of ten subjects ~~with~~ and an Initial Data Safety Monitoring Board, (DSMB), review of safety on the first three subjects once they have reached 6 months follow-up. We do not intend to interrupt our trial waiting for the DSMB report. Our management’s approach is to set up the trials so as to allow for a seamless transition into commercial production upon approval. We have arranged for sufficient Bovine Closed Herd corium to produce sufficient collagen scaffolds to meet our needs for the clinical trials once the IND is approved.

~~Our~~Three ~~management~~board ispositions ~~considering various~~remain ~~possibilities~~open ~~and~~on ~~approaches~~our toBoard ~~obtaining clinical trial materials and manufacturing. While no final decision has been made,~~of ~~management’s approach is to set up the trials so as to allow for a seamless transition into commercial production upon approval~~Directors.

WeImportantly, ~~have~~we ~~access~~are tofiling athis ~~clean~~annual ~~room~~report ~~facility~~without our auditor’s review or any audit of our financial information or this report. Our reason for doing this is that we are still negotiating ~~growing~~with ~~NovaDerm~~our ~~here~~potential inauditors ~~New~~for ~~Jersey~~the incompletion ~~addition~~of toan ~~instate~~audit and ~~out~~review of ~~state~~our ~~FDA~~unaudited ~~registered~~past ~~contract~~years ~~manufacturers.~~reports ~~Our~~prior ~~selection~~to ~~for~~obtaining an audit ~~the~~of ~~clinical~~this ~~trial~~current ~~material~~10K ~~manufacturer~~filing. ~~must~~Instead, we have ~~the~~provided ~~ability~~herein toinformation ~~produce~~as ~~marketable~~typically ~~material~~presented ~~when~~in ~~NovaDerm~~our is10Q ~~approved~~quarterly ~~for~~report, ~~sale~~including financial information, which has not been reviewed or audited by ~~the~~ ~~FDA~~any independent outside source.

We intend, if and when complete, to file an amendment to this 10Q filing with such reviewed and audited information. We are unaware at this time when we will obtain the necessary review and audit of the current and past filings; however, we will continue to provide current information to investors and the public when we are able through either our EDGAR filings and/or through postings on our website.

Table of Contents

Results of Operations for the Three ~~and Nine~~ Months Ended ~~June~~December 3031, 2022 and 2021

We generated no revenues from September 6, 2007 (date of inception) to ~~June~~December 3031, 2022. We do not expect to generate ~~revenues~~revenue until we are able to obtain FDA approval of our product ~~and thereafter successfully market and sell the product~~.

We incurred operating expenses of $~~152~~267,~~721~~619 ~~and $454,766~~ for the three ~~and nine~~ months ended ~~June~~December 3031, 2022, compared with operating expenses of $~~155~~146,~~559 and $~~532~~,113~~ for the three ~~and nine~~ months ended ~~June~~December 3031, 2021. General and administrative expenses accounted for all of our operating expenses. The ~~decrease~~major ~~was~~difference and shift in operating expenses from the ~~result~~three ofmonths aended ~~decrease~~December in31, ~~insurance~~2021 was accounted for by lower general and administrative expense. Otherwise, all operating expenses during the three months ended December 31, 2022 were from general and ~~stock-based~~administrative ~~compensation~~expenses in the amount of $267,619.

~~Other~~Net ~~expenses~~other expense was $109,~~372 and~~895 ~~$29,101~~ for the three ~~and nine~~ months ended ~~June~~December 3031, 2022, as compared to net other ~~expenses~~expense of $97,~~786~~593 ~~and $26,414~~ for the three ~~and nine~~ months ended ~~June~~December 3031, 2021. Other income (and expenses) for the three months ended December 31, 2022 consisted of interest ~~expense~~expenses of $9,395 and an unrealized loss on securities. ~~The~~of ~~increase in~~$500. ~~interest~~Other ~~expense~~income ~~related~~and ~~primarily~~expenses tofor ~~interest~~the ~~charged~~same onperiod aended ~~convertible~~2021 ~~note~~consisted ~~issued~~of tointerest ~~John~~expense ~~Weber~~of $8,943 ~~the~~and ~~Company’s chief financial~~an ~~officer,~~unrealized gain on ~~March~~securities ~~31,~~of ~~2020~~$1,350.

After provision for preferred stock dividends of $17,845,we recorded net loss of $295,359 for the three months ended December 31, 2022. By comparison, we recorded net loss of $171,970 for the three months ended December 31, 2021. Our net loss for the quarter ended December 31, 2021 was primarily the result of general and administrative expense.

Liquidity and Capital Resources

As of ~~June~~December 3031, 2022, we had cash of $111,~~643.~~793,901 Atand ~~September~~total 30current assets of $11,794,326. ~~2021~~As of December 31, 2022, we had ~~cash~~current liabilities of $117,~~859~~668,980. We therefore had a working capital deficit of $5,874,654.

Operating activities used $27361,~~216~~ 792 in cash for the ~~nine~~three months ended ~~June~~December 3031, 2022. The decrease in cash was primarily attributable to funding the loss for the period.

~~There~~Investing ~~were~~activities noand ~~investing~~ financing activities provided no cash or cost during the reported period. We note that the value of the shares of Amarantus we obtained and which created income from that sale of assets transaction have declined significantly in value since the consummation of the agreement.

~~Cash~~We ~~flows~~have ~~from~~issued various promissory notes to meet our short-term demands, the terms of which are provided in the notes to the consolidated financial statements accompanying this report. While this source of bridge financing ~~activities~~has ~~for~~been helpful in the short term to meet our financial obligations, we will need additional financing ~~nine~~to ~~months~~fund ~~ended~~our ~~June~~operations, 30continue with the FDA approval process, ~~2022~~and ~~represents~~implement ~~proceeds~~our ~~from~~business ~~loans~~plan. ~~from~~Our ~~officers~~long-term offinancial needs are estimated at about $~~27,000~~8-10 million.

We have issued various promissory notes to meet our short term demands, the terms of which are provided in the notes to the consolidated financial statements accompanying this report. While this source of financing has been helpful in the short term to meet our financial obligations, we will need additional financing to fund our operations, continue with the FDA approval process, and implement our business plan. Our long term financial needs are estimated at about $8-10 million.

Table of Contents

Off Balance Sheet Arrangements

As of ~~June~~December 3031, 2022, there were no off-balance sheet arrangements.

Going Concern

Our consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred operating losses from inception, expect to incur further losses in the development of our business, and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A smaller reporting company is not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in ~~Exchange~~ Exchange Act Rules 13a-15(e) and 15d-15(e)) as of ~~June~~December 3031, 2022. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of ~~June~~December 3031, 2022, our disclosure controls and procedures were not effective due ~~primarily~~ to ~~the lack of segregation of duties, resulting in the~~ presence of material weaknesses in internal control over financial reporting.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be ~~prevented~~ prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of ~~June~~December 3031, 2022, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending September 30, ~~2022~~2023 assuming we are able to obtain necessary funding or alternative financing: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

We are unable to remedy our controls related to the inadequate segregation of duties and ineffective risk management until we ~~receive~~have ~~financing~~ hired sufficient qualified staff to ~~hire~~perform ~~additional~~the ~~employees~~necessary functions.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended ~~June~~December 3031, 2022 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

Item 1A. Risk Factors

A smaller reporting company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~None~~The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.

For the three months ended December 31, 2022, no shares of common stock have been issued for the conversion of principal issued under our bridge financing and accrued interest.

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders expressed their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number	Description of Exhibit
31.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101**	The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended ~~June~~December 3031, 2022 formatted in ~~Extensible~~Inline eXtensible Business Reporting Language (~~XBRL~~iXBRL).
**Provided herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Regenicin, Inc.
Date:	~~August~~February 1213, ~~2022~~2023
By:	/s/ Randall McCoy
	Randall McCoy
Title:	Chief Executive Officer and Director (Principal Executive Officer)

By:	/s/ John J. Weber
	John J. Weber
Title:	Chief Financial Officer and Director (Principal Financial Officer)

Table of Contents

Filing Compare · Regenicin, Inc.